GenMark Diagnostics to Participate in the Cowen Health Care Conference
Get Alerts GNMK Hot Sheet
Join SI Premium – FREE
CARLSBAD, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts.
GenMark’s management is scheduled to present on Tuesday, March 3, 2020 at 10:40am ET. Interested parties can access a live and archived webcast of the presentation at ir.genmarkdx.com.
About GenMark Diagnostics
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Leigh Salvo
(415) 937-5404
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Firm Capital Apartment REIT Reports Q2/2026 Results and Announces Name Change
- NurExone Announces Closing of C$1,066,078 Private Placement
- Evolution Petroleum Closes Strategic Acquisition of Midland Basin Mineral & Royalty Interests
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share